

Ipsen announces its corporate agenda for 2017

Paris (France), 13 December 2016 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today its corporate agenda* for 2017:

- 23 February 2017: Full year 2016 sales & results
- 27 April 2017: First quarter 2017 sales
- 7 June 2017: General shareholders' meeting
- 13 June 2017: Payment of 2016 dividend**
- 27 July 2017: First half 2017 sales & results
- 26 October 2017: First nine months 2017 sales

* This financial calendar is for indicative purposes only and the Group could change its publication dates should it deem it necessary

** Pending approval of the Board of directors (22 February 2017) and of the General shareholders' meeting (7 June 2017)

About Ipsen

Ipsen is a global specialty-driven pharmaceutical group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology (adult & pediatric). Ipsen's commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2015, R&D expenditure totaled close to €193 million. The Group has more than 4,600 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

For further information:

Media

Didier Véron

Senior Vice-President, Public Affairs
and Communication
Tel.: +33 (0)1 58 33 51 16
E-mail: didier.veron@ipsen.com

Brigitte Le Guennec

Corporate External Communication Manager
Tel.: +33 (0)1 58 33 51 17
E-mail : brigitte.le.guennec@ipsen.com

Financial Community

Eugenia Litz

Vice-President Investor Relations
Tel.: +44 (0) 1753 627721
E-mail: eugenia.litz@ipsen.com

Côme de La Tour du Pin

Investor Relations Manager
Tel.: +33 (0)1 58 33 53 31
E-mail: come.de.la.tour.du.pin@ipsen.com